# 11th annual california cancer consortium conference

# "Recent Advances and New Directions in Cancer Therapy"



## Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center SACRAMENTO, CA

City of Hope Comprehensive Cancer Center DUARTE, CA

University of Southern California/Norris Comprehensive Cancer Center Los Angeles, CA

University of Pittsburgh Cancer Institute/UPMC PITTSBURGH, PA

Barbara Ann Karmanos Comprehensive Cancer Center (Wayne State University)
Detroit, MI

Penn State Hershey Cancer Institute (Penn State University)
HERSHEY, PA

CALIFORNIA CANCER CONSORTIUM CONFERENCE

Educational Steering Committee and Conference Chairs:

Primo Lara, Jr., M.D. | Edward Newman, Ph.D. Robert Morgan, M.D.

Sponsored by: THE MEDICAL EDUCATOR CONSORTIUM



#### EDUCATIONAL STEERING COMMITTEE & CONFERENCE CHAIRS

#### Primo Lara, Jr., M.D.

Professor of Medicine
University of California Davis
School of Medicine
Associate Director for Translational Research
University of California Davis
Comprehensive Cancer Center
Sacramento, CA

#### Edward Newman, Ph.D.

Associate Professor, Cancer Biology Developmental Cancer Therapeutics Program Co-Leader City of Hope Comprehensive Cancer Center Duarte, CA

#### Robert Morgan, M.D.

Professor of Medicine, Department of Medical Oncology and Therapeutics Research Co-director, Gynecological Cancers Program City of Hope Comprehensive Cancer Center, Duarte, CA

## **DISTINGUISHED FACULTY**

#### Edwin Alvarez, M.D.

Assistant Professor, Department of Obstetrics and Gynecology Division of Gynecologic Oncology UC Davis Comprehensive Cancer Center Sacramento, CA

#### Afsaneh Barzi, M.D., Ph.D.

Assistant Professor of Medical Oncology, Department of Medicine, Division of Oncology USC Norris Comprehensive Cancer Center Los Angeles, CA

#### Chandra Belani, M.D.

Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center Deputy Director and Associate Director of Clinical Research, Penn State Hershey Cancer Institute Hershey, PA

#### M. Suzette Blanchard, Ph.D.

Associate Research Professor, Division of Biostatistics, City of Hope Comprehensive Cancer Center
Duarte, CA

#### Preet M. Chaudhary, M.D., Ph.D.

Chief, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases Professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research Program Director, USC/Norris Blood and Marrow Transplant Program Co-leader, Molecular Genetics Program, Norris Comprehensive Cancer Center Keck School of Medicine of USC, University of Southern California Los Angeles, CA

#### Helen Chew, M.D.

Professor of Medicine, Division of Hematology/Oncology UC Davis Comprehensive Cancer Center Sacramento, CA

#### Mihaela Cristea, M.D.

Associate Clinical Professor, Medical Oncology, Lung Cancer and Thoracic Oncology Program Gynecologic Oncology, Gynecological Oncology/Peritoneal Malignancy Program City of Hope Comprehensive Cancer Center Duarte, CA

#### Savita Dandapani, M.D.

Assistant Professor, Radiation Oncology City of Hope Comprehensive Cancer Center Duarte, CA

#### Tanya Dorff, M.D.

Assistant Professor University of Southern California Keck School of Medicine, USC Norris Comprehensive Cancer Center Los Angeles, CA

#### Anthony El-Khoueiry, M.D.

Assistant Professor, University of Southern California Keck School of Medicine USC Norris Comprehensive Cancer Center Los Angeles, CA

#### Marwan Fakih, M.D.

Interim Chair and Professor,
Medical Oncology and Therapeutics Research
Section Head, GI Medical Oncology
Co-Director, GI Cancers Program
City of Hope Comprehensive
Cancer Center
Duarte, CA

## Agustin Garcia, M.D., MMM

Professor of Medicine Section Chief of Hematology/Oncology Louisana State University New Orleans, LA

#### Barbara J. Gitlitz, M.D.

Associate Professor of Medicine, USC Keck School of Medicine Los Angeles, CA

#### Susan Groshen, Ph.D.

Professor of Research, Department of Preventive Medicine, University of Southern California, USC Norris Comprehensive Cancer Center Los Angeles, CA

#### Elisabeth I. Heath, M.D., FACP

Hartmann Endowed Chair for Prostate Cancer Research, Professor of Oncology and Medicine, Director, Prostate Cancer Research, Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI

#### James Hu, M.D.

University of Southern California USC Norris Comprehensive Cancer Center Los Angeles, CA

#### Syma Iqbal, M.D., FACP

Associate Professor of Clinical Medicine Program Director, Medical Oncology Fellowship USC/Keck School of Medicine, USC Norris Comprehensive Cancer Center Division of Medical Oncology Los Angeles, CA

#### Brian Jonas, M.D., Ph.D.

Assistant Professor of Medicine, Division of Hematology/Oncology, UC Davis Comprehensive Cancer Center Sacramento, CA

#### Michael Kahn, Ph.D.

Professor of Biochemistry and Molecular Biology Provost's Professor of Medicine and Pharmacy Co-Chair, GI Oncology Program USC Norris Comprehensive Cancer Center USC Center for Molecular Pathways and Drug Discovery Los Angeles, CA

#### Karen Kelly, M.D.

Professor of Medicine Associate Director for Clinical Research Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research UC Davis Comprehensive Cancer Center, Sacramento, CA

#### Kevin Kelly, M.D., Ph.D.

Associate Professor of Clinical Medicine Assistant Medical Director of Clinical Investigations Support Office, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Los Angeles, CA

#### Edward Kim, M.D., Ph.D.

Assistant Professor, Division of Hematology and Oncology UC Davis Comprehensive Cancer Center, Sacramento, CA

#### Marianna Koczywas, M.D.

Clinical Professor
City of Hope
Department of Medical Oncology and
Therapeutics Research
Thoracic Oncology and Lung
Cancer Program
Duarte, CA

#### Shivaani Kummar, M.D.

Professor, Department of Medicine Director, Phase I Clinical Research Program Stanford University School of Medicine Stanford, CA

#### Primo N. Lara, Jr., M.D.

Professor of Medicine, UC Davis School of Medicine Associate Director for Translational Research, UC Davis Comprehensive Cancer Center Sacramento, CA

#### Heinz-Josef Lenz, M.D., Ph.D.

Professor of Medicine and Preventive Medicine/ Section Head of GI Oncology, University of Southern California Keck School of Medicine Associate Director for Clinical Research USC Norris Comprehensive Cancer Center Los Angeles, CA

#### Jeffrey Longmate, Ph.D.

Professor and Director Division of Biostatistics, Department of Information Sciences Beckman Research Institute/City of Hope Comprehensive Cancer Center Duarte, CA

#### Philip C. Mack, Ph.D.

Associate Adjunct Professor UC Davis Comprehensive Cancer Center Sacramento, CA

#### Robert Morgan, M.D.

Professor of Medicine, Department of Medical Oncology and Therapeutics Research Co-director, Gynecological Cancers Program City of Hope Comprehensive Cancer Center Duarte. CA

#### Edward Newman, Ph.D.

Developmental Cancer Therapeutics
Program Co-Leader
City of Hope Comprehensive Cancer Center
Duarte, CA

#### Philip Philip, M.D.

Professor of Medicine, Wayne State University School of Medicine, Detroit, MI Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute Detroit. MI

## Leslie Popplewell, M.D., FACP

Hematology and Hematopoietic Cell Transplantation City of Hope Comprehensive Cancer Center Duarte, CA

#### David Quinn, MBBS, Ph.D.

Associate Professor and Head Section of GU Medical Oncology, USC Keck School of Medicine, Los Angeles, CA; Leader Developmental Therapeutics Program, USC Norris Comprehensive Cancer Center Los Angeles, CA

#### Jonathan W. Riess, M.D., MS

Assistant Professor of Medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA

#### Steven T. Rosen, M.D.

Provost & Chief Scientific Officer
Director, Comprehensive Cancer Center and
Beckman Research Institute
Irell & Manella Cancer Center Director's
Distinguished Chair, City of Hope
Comprehensive Cancer Center
Duarte, CA

## Sarmad Sadeghi, M.D., Ph.D.

Assistant Professor, University of Southern California, Division of Oncology USC Norris Comprehensive Cancer Center, Los Angeles, CA

#### Thomas Semrad, M.D., MAS, FACP

Assistant Professor of Medicine Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center Sacramento, CA

#### Tanya Siddiqi, M.D.

Assistant Professor Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, City of Hope Comprehensive Cancer Center Duarte, CA

#### George Somlo, M.D.

Professor, Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA

#### Cy A. Stein, M.D., Ph.D.

Professor, Department of Medical Oncology Therapeutics Research City of Hope Medical Center Duarte, CA

#### Timothy Synold, Pharm.D.

Professor, Cancer Biology
Director, Analytical Pharmcology Core Facility
City of Hope Comprehensive Cancer Center
Duarte, CA

#### Ahmad Tarhini, M.D., Ph.D.

Associate Professor, Department of Medicine, Hematology-Oncology Clinical and Translational Science Institute, University of Pittsburgh School of Medicine Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute UPMC Cancer Pavilion Pittsburgh, PA

#### Joseph Tuscano, M.D.

Professor of Medicine
Division of Hematology and Oncology,
UC Davis School of Medicine/
UC Davis Comprehensive Cancer Center
Sacramento, CA

#### Przemyslaw Twardowski, M.D.

Clinical Professor of Medical Oncology, City of Hope Medical Center Duarte, CA

#### Ulka Vaishampayan, M.D.

Associate Professor of Medicine, Wayne State University School of Medicine Barbara Ann Karmanos Cancer Institute Detroit, MI

#### Antoinette Wozniak, M.D.

Barbara Ann Karmanos Cancer Center Detroit, MI

#### Hong Zheng, M.D., Ph.D

Assistant Professor of Medicine
Division of Hematology/Oncology, Penn State
Hershey Cancer Institute
Penn State University College of Medicine
Hershey, PA

## 11th Annual California Cancer Consortium Conference

# "Recent Advances and New Directions in Cancer Therapy"

#### COURSE DESCRIPTION

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

#### **EDUCATIONAL OBJECTIVES**

After participating in this educational activity, you should be able to:

- Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of many individual tumor types, and identify specific opportunities for therapeutic intervention.
- Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of your patients with cancer.
- Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of your patients with cancer.
- Discuss the new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

#### TARGET AUDIENCE

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

#### **NEEDS ASSESSMENT**

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was

specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently improve patient outcomes.

#### **ACCREDITATION**

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **CREDIT HOURS**

The Medical Educator Consortium designates this educational activity for a maximum of 15 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

# NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is *AMA PRA Category I Credits*<sup>TM</sup>, and has been taken within the appropriate time frames.

# 11th Annual California Cancer Consortium Conference

"Recent Advances and New Directions in Cancer Therapy"

# FRIDAY, AUGUST 7th, 2015

11:00 am 12:00 - 1:00 pm 1:00 pm	Registration Opens & Visit Exhibits  Lunch Symposia (non CME)  Welcome and Introductions  Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope),  Robert Morgan, M.D. (City of Hope)
1:15 pm	SESSION 1: LUNG CANCER Chair: Jonathan W. Riess (UC Davis)
1:20 - 1:35 pm 1:35 - 1:40 pm 1:40 - 1:55 pm 1:55 - 2:00 pm 2:00 - 2:15 pm 2:15 - 2:20 pm	Squamous Cell Lung Cancer: Emerging Developments  Marianna Koczywas, M.D. (City of Hope)  Question and Answer  Non-Squamous Non-Small Cell Lung Cancer: Beyond EGFR and ALK  Chandra Belani, M.D. (Penn State University)  Question and Answer  What's New in Small Cell Lung Cancer Therapeutics?  Antoinette Wozniak, M.D. (Karmanos Cancer Center)  Question and Answer
2:20 pm	SESSION 2: GENITOURINARY CANCERS (I) Chair: Ulka Vaishampayan, M.D. (Karmanos Cancer Center)
2:25 - 2:40 pm 2:40 - 2:45 pm 2:45 - 3:00 pm 3:00 - 3:05 pm 3:05 - 3:20 pm	Drug Development in Castration Resistant Prostate Cancer <i>Przemyslaw Twardowski, M.D. (City of Hope)</i> Question and Answer New Developments in Urothelial Cancer Therapeutics <i>Sarmad Sadeghi, M.D. (University of Southern California)</i> Question and Answer Refreshment Break, Visit Exhibits
3:20 pm	SESSION 3: GASTROINTESTINAL CANCERS (I) Chair: Heinz Josef Lenz, M.D. (University of Southern California)
3:20 - 3:35 pm 3:35 - 3:40 pm 3:40 - 3:55 pm 3:55 - 4:00 pm	Hepatocellular and Hepatobiliary Cancers  Anthony El-Khoueiry, M.D. (University of Southern California)  Question and Answer  Adenocarcinoma of the Pancreas: New Developments  Edward Kim, M.D. (UC Davis)  Question and Answer
4:00 pm	SESSION 4: NOVEL TARGETS IN ONCOLOGY DRUG DEVELOPMENT (I) Chair: Barbara Gitlitz, M.D. (University of Southern California)
4:00 - 4:15 pm 4:15 - 4:30 pm 4:30 - 4:45 pm	Anti-mitotic Agents: Eribulin, Tubulin Inhibitors  David Quinn, M.D. (University of Southern California)  AR-V7 as a Target in Prostate Cancer  Cy A. Stein, M.D. (City of Hope)  Next-Generation M.D. (IGED)  Next-Generation M.D. (IGED)
4:45 - 5:00 pm 5:00 - 5:30 pm 5:30 - 6:30 pm	Jonathan Riess, M.D. (UC Davis) Next-Generation Angiogenesis Inhibitors Tanya Dorff, M.D. (University of Southern California) PANEL DISCUSSION: Better Targets or Just Newer? (Session Faculty) Welcome Reception, Visit Exhibits

	SATURDAY, AUGUST 8th, 2015
7:00 am 7:00 - 8:00 am 8:00 am	Registration & Visit Exhibits  Breakfast Symposium (non CME)  Welcome and Introductions  Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope),  Robert Morgan, M.D. (City of Hope)
8:05 am	SESSION 5: INNOVATIVE CLINICAL TRIAL DESIGNS FOR THE GENOMIC ERA Chairs: Jeff Longmate, Ph.D. (City of Hope), Susan Groshen, Ph.D. (University of Southern California)
8:10 - 8:20 am 8:20 - 8:30 am 8:30 - 8:40 am 8:40 - 9:05 am	Novel Dose Escalation Strategies  Jeff Longmate, Ph.D. (City of Hope)  Biostatistical Considerations for Phase II Trials  Susan Groshen, Ph.D. (University of Southern California)  Basket vs Umbrella Clinical Trials  M. Suzette Blanchard, Ph.D. (City of Hope)  PANEL DISCUSSION: Optimal Clinical Trial Designs  Session Faculty
9:05 am	SESSION 6: HEMATOLOGIC MALIGNANCIES (I) Chair: Joseph Tuscano, M.D. (UC Davis)
9:10 - 9:25 am 9:25 - 9:30 am 9:30 - 9:45 am 9:45 - 9:50 am	Novel Agents in Development for Acute Leukemia Brian Jonas, M.D. (UC Davis) Question and Answer Chronic B- and T-cell Leukemias: New Developments Kevin Kelly, M.D. (University of Southern California) Question and Answer
9:50 am	SESSION 7: GENITOURINARY CANCER (II) Chair: Primo Lara, Jr., M.D. (UC Davis)
9:55 - 10:10 am 10:10 - 10:15 am 10:15 - 10:30 am 10:30 - 10:35 am 10:35 - 10:50 am	Renal Cell Cancer: New Agents in Development  Tanya Dorff, M.D. (University of Southern California)  Question and Answer  Prostate Cancer: New Therapeutics for the Pre-Castrate Resistant Prostate  Cancer Patient  Elisabeth Heath, M.D. (Wayne State University)  Question and Answer  Refreshment Break, Visit Exhibits
10:50 am	SESSION 8: GASTROINTESTINAL CANCER (II) Chairs: Thomas Semrad, M.D. (UC Davis) Afsaneh Barzi, M.D. (University of Southern California)
10:55 - 11:10 am 11:10 - 11:15 am 11:15 - 11:30 am 11:30 - 11:35 am	Emerging Developments in Metastatic Colorectal Cancer Syma Iqbal, M.D. (University of Southern California) Question and Answer State of the Art Management of Upper GI Tract Cancers (Gastric, GE Junction, Neuroendocrine Pancreatic Tumors) Philip Philip, M.D. (Wayne State University) Question and Answer
11:35 am	SESSION 9: CANCER IMMUNOTHERAPY Chair: Leslie Popplewell, M.D. (City of Hope)
11:40 - 11:55 am	Checkpoint Inhibitors: Current Status and Future Directions Karen Kelly, M.D. (UC Davis)

11:55 am - 12:00 pm 12:00 - 12:15 pm 12:15 - 12:20 pm 12:20 - 12:35 pm 12:35 - 12:40 pm 12:40 - 1:20 pm 1:20 - 1:35 pm	Question and Answer Cancer Vaccines and T-Cell Based Approaches  Mihaela Cristea, M.D. (City of Hope) Question and Answer Antibody-Drug Conjugates  Tanya Siddiqi, M.D. (City of Hope) Question and Answer  Lunch Symposia (non cme) Coffee & Dessert, Visit Exhibits	
1:35 pm	SESSION 10: HEMATOLOGIC MALIGNANCIES (II) Chair: Leslie Popplewell, M.D. (City of Hope)	
1:40 - 1:55 pm 1:55 - 2:00 pm 2:00 - 2:15 pm 2:15 - 2:20 pm 2:20 - 2:35 pm 2:35 - 2:40 pm	New Molecular Agents for Malignant Lymphoma  Steven Rosen, M.D. (City of Hope)  Question and Answer  Multiple Myeloma: Latest and Greatest  Joseph Tuscano, M.D. (UC Davis)  Question and Answer  Follicular Lymphoma: Latest and Greatest  Hong Zheng, M.D. (Penn State University)  Question and Answer	
2:40 pm	SESSION 11: GYNECOLOGIC CANCER Chair: Robert Morgan, M.D. (City of Hope)	
2:45 - 3:00 pm 3:00 - 3:05 pm 3:05 - 3:20 pm 3:20 - 3:25 pm	Refractory Ovarian Cancer: New Approaches  Agustin Garcia, M.D. (Louisana State University)  Question and Answer  Endometrial and Cervix Cancers  Edwin Alvarez, M.D. (University of Southern California)  Question and Answer	
3:25 - 3:40 pm	SESSION 12: BEST OF THE CALIFORNIA CANCER CONSORTIUM (II) Chair: Robert Morgan, M.D. (City of Hope) Fellow-led Presentation of CCC Research Presented by Jonathan W. Riess, M.D. & Thomas Semrad, M.D. (UC Davis)	
3:40 - 3:55 pm	Refreshment Break, Visit Exhibits	
3:55 pm	SESSION 13: CLINICAL AND MOLECULAR PHARMACOLOGY Co-Chairs: Edward Newman, M.D. (City of Hope) Tim Synold, M.D. (City of Hope)	
4:00 - 4:10 pm 4:10 - 4:20 pm	Optimizing Preclinical Cancer Models  *Philip Mack, Ph.D. (UC Davis)*  Specimen Collection and Molecular Phenotyping for Clinical Trials,  Circulating DNA	
4:20 - 4:30 pm 4:30 - 4:40 pm	Shivaani Kummar, M.D. (Stanford) Adaptive control: The Original Personalized Medicine Tim Synold, Pharm.D. (City of Hope) PANEL DISCUSSION: Biomarker and PK Correlative Studies in the Era of Reduced Funding Session Faculty	
5:10 pm	Adjourn for Day	

OTTO TO ATT	ATTOTTOM AL	
SUNDAY	, AUGUST 9th	. 2015
OUTIDITI	, modour ,	, <del>_</del>

7:00 am Registration, Visit Exhibits 7:00 - 8:00 am Breakfast Symposium (non cme) Welcome and Introductions 8:00 am Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope), Robert Morgan, M.D. (City of Hope) SESSION 15: NOVEL TARGETS IN ONCOLOGY DRUG 8:05 am DEVELOPMENT (II) Chair: Edward Newman, M.D. (City of Hope) 8:10 - 8:25 am Fibroblast Growth Factor Inhibitors Thomas Semrad, M.D. (UC Davis) 8:25 - 8:40 am WNT signalling Michael Kahn, M.D. (University of Southern California) 8:40 - 8:55 am Targeting DNA Repair: ADR Inhibitors (Radiosensitizers) Savita Dandapani, M.D. (City of Hope) State of MEK Inhibitors in CRC 8:55 - 9:10 am Marwan Fakih, M.D. (City of Hope) 9:10 - 9:25 am Question and Answer (session faculty) 9:25 am SESSION 16: NEW DEVELOPMENTS IN HEMATOLOGY/ ONCOLOGY Chair: Primo Lara, M.D. (UC Davis) 9:30 - 9:45 am Malignant Melanoma: Latest and Greatest Ahmad Tarhini, M.D. (University of Pittsburg) 9:45 - 9:50 am **Question and Answer** 9:50 - 10:05 am Targeted Drug Development for KSHV-Associated Malignancies Preet M. Chaudhary, M.D. (University of Southern California) 10:05 - 10:10 am **Question and Answer** 10:10 - 10:25 am Refreshment Break, Visit Exhibits 10:25 - 10:40 am Soft Tissue Sarcoma: Latest and Greatest James Hu, M.D. (University of Southern California) 10:40 - 10:45 am Ouestion and Answer 10:45 am SESSION 17: BREAST CANCER Co-chairs: George Somlo, M.D. (City of Hope), Helen Chew, M.D. (UC Davis) 10:50 - 11:05 am Emerging Treatments for Metastatic Triple Negative Breast Cancer George Somlo, M.D. (City of Hope) 11:05 - 11:10 am Question and Answer 11:10 - 11:25 am HER2 Positive Breast Cancer: New Standards of Care Helen Chew, M.D. (UC Davis) 11:25 - 11:30 am Question and Answer 11:30 - 11:55 am SESSION 18: PANEL DISCUSSION: New Directions of the NCI in the Team Science Era Faculty: Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope),

Heinz Josef-Lenz, M.D. (City of Hope), Chandra Belani, M.D. (Penn State),

11:55 am - 12:00 pm Closing Remarks and Adjourn

Robert Morgan, M.D. (City of Hope)

## HOTEL INFORMATION



#### THE WESTIN PASADENA

191 N Los Robles Avenue Pasadena, CA 91101

Reservation: 866.837.4181

The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center, where you can put tasks behind you with

ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena's charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of \$179 single or double room plus tax, European Plan (no meals). The cutoff date to make reservations is July 6th, 2015, after this date reservations are subject to hotel availability.

Make your hotel reservations by calling 866.837.4181 and use group code "CA Cancer Consortium Conference"

#### **CONFERENCE MANAGEMENT**

MEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)

1550 S Dixie Highway Suite 202 Coral Gables, FL 33146 Telephone: 305.663.1628 Fax: 305.675.2718

Website: www.meccinc.com Email: tvalls@meccinc.com

Register online at www.meccinc.com under conference information and registration.

# 11th Annual California Cancer Consortium Conference

# "Recent Advances and New Directions in Cancer Therapy"

August 7-9, 2015, The Westin Pasadena, Pasadena, CA

# Registration Form

Name		Degree
License Number		State
Address		
Telephone ()		Fax ()
Email		
Specialty		
TYPE OF PRACTICE:	☐ Private	
REGISTRATION FEE:		
REGISTRATION TEE.	□ \$175	Physician
		Nurse, Nurse Practitioner, Resident, Fellow,
		Students, Non-physician researchers and staff
		(e.g., CRAs)
	<b>□</b> \$250	Industry Professional
-		to July 6th, 2015. A \$50 administrative charge will be fier July 6th no refunds will be provided.
I authorize MECC to charg course using the following o		ard i/a/o \$ for the registration of this
Name as it appear on the ca	ırd	Exp. Date
Card number		CVV Code:
Authorized signature		

For those requiring special assistance, contact MECC at 305.663.1628 or via email tvalls@meccinc.com no later than July 6th, 2015.

Meetings, Events and Conference Coordinators, Inc. P.O. Box 430376 Miami, FL 33243-0376

PRST STD
US Postage
PAID
Miami, FL
Permit No. 1429

11th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE "Recent Advances and New Directions in Cancer Therapy"

August 7-9, 2015

The Westin Pasadena, Pasadena, CA